InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,036.23
(
0.36%
)
US TECH 100
16,960.80
(
0.59%
)
Dow Jones
38,022.59
(
0.31%
)
Brent Oil
83.45
(
-0.11%
)
Bitcoin
58,462.84
(
0.39%
)
Post# of 251673
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: spongepaul post# 211353

Tuesday, 05/16/2017 7:04:28 PM

Tuesday, May 16, 2017 7:04:28 PM

Post# of 251673
(CHRS/MNTA/AMGN/etc)—Re: ABBV’s ‘135 Humira patent invalidated

This is bullish for all companies seeking to commercialize Humira FoBs for the US market (as noted in #msg-131355570).

Had ABBV’s ‘135 patent been upheld (or should ABBV prevail on appeal to the CAFC, which is very unlikely, IMO), then Humira-FoB labels would have excluded biweekly subcutaneous dosing to treat RA, which is Humira’s largest single indication.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up